Wang Yue, Liu Tao, Jiao Guangming, Lv Yingguang, Piao Chenxi, Lu Xiangyu, Ma Haiyang, Wang Hongbin
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, PR China.
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, PR China.
Life Sci. 2023 May 15;321:121618. doi: 10.1016/j.lfs.2023.121618. Epub 2023 Mar 24.
Hepatic ischemia-reperfusion injury (IRI) impairs postoperative recovery of liver function after liver resection or transplantation. It is crucial to minimize liver injury during surgery in order to improve patient survival and quality of life. The aim of this study was to explore the therapeutic efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSCs-exo) against hepatectomy combined with IRI injury and compare that with the effect of adipose-derived mesenchymal stem cells (ADSCs).
Minimally invasive hemihepatectomy combined with hepatic IRI was established in minipigs. A single dose of ADSCs-exo, ADSCs or PBS was injected through the portal vein. The histopathological features and function of the liver, and the oxidative stress levels, endoplasmic reticulum (ER) ultrastructure and ER stress (ERS) response were analyzed pre- and postoperatively.
ADSCs-exo alleviated the histopathological injuries and ultrastructural changes in the ER, and significantly improved ALP, TP and CAT levels. Furthermore, ADSCs-exo treatment also downregulated ERS-related factors such as GRP78, ATF6, IRE1α/XBP1, PERK/eIF2α/ATF4, JNK and CHOP. The therapeutic effects of ADSCs-exo and ADSCs were similar.
Intravenous administration of a single dose of ADSCs-exo is a novel cell-free therapeutic approach to improve surgery-related liver injury. Our findings provide evidence of the paracrine effect of ADSCs and an experimental basis for treating liver injury with ADSCs-exo instead of ADSCs.
肝缺血再灌注损伤(IRI)会损害肝切除或肝移植术后肝功能的恢复。在手术期间尽量减少肝损伤对于提高患者生存率和生活质量至关重要。本研究的目的是探讨脂肪间充质干细胞来源的外泌体(ADSCs-exo)对肝切除联合IRI损伤的治疗效果,并与脂肪间充质干细胞(ADSCs)的效果进行比较。
在小型猪中建立微创半肝切除联合肝IRI模型。通过门静脉注射单剂量的ADSCs-exo、ADSCs或PBS。对术前和术后肝脏的组织病理学特征和功能、氧化应激水平、内质网(ER)超微结构和内质网应激(ERS)反应进行分析。
ADSCs-exo减轻了ER的组织病理学损伤和超微结构变化,并显著提高了碱性磷酸酶(ALP)、总蛋白(TP)和过氧化氢酶(CAT)水平。此外,ADSCs-exo治疗还下调了与ERS相关的因子,如葡萄糖调节蛋白78(GRP78)、活化转录因子6(ATF6)、肌醇需求酶1α/ X盒结合蛋白1(IRE1α/XBP1)、蛋白激酶RNA样内质网激酶/真核翻译起始因子2α/活化转录因子4(PERK/eIF2α/ATF4)、应激活化蛋白激酶(JNK)和Caspase-12(CHOP)。ADSCs-exo和ADSCs的治疗效果相似。
静脉注射单剂量的ADSCs-exo是一种改善手术相关肝损伤的新型无细胞治疗方法。我们的研究结果为ADSCs的旁分泌作用提供了证据,并为用ADSCs-exo而非ADSCs治疗肝损伤提供了实验依据。